Cargando…

NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation

Glioblastoma multiforme (GBM) is a highly heterogeneous disease with a mesenchymal subtype tending to exhibit more aggressive and multitherapy-resistant features. Glioblastoma stem-cells derived from mesenchymal cells are reliant on iron supply, accumulated with high reactive oxygen species (ROS), a...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, I-Chang, Su, Yu-Kai, Setiawan, Syahru Agung, Yadav, Vijesh Kumar, Fong, Iat-Hang, Yeh, Chi-Tai, Lin, Chien-Min, Liu, Heng-Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178261/
https://www.ncbi.nlm.nih.gov/pubmed/37175412
http://dx.doi.org/10.3390/ijms24097706
_version_ 1785040819671007232
author Su, I-Chang
Su, Yu-Kai
Setiawan, Syahru Agung
Yadav, Vijesh Kumar
Fong, Iat-Hang
Yeh, Chi-Tai
Lin, Chien-Min
Liu, Heng-Wei
author_facet Su, I-Chang
Su, Yu-Kai
Setiawan, Syahru Agung
Yadav, Vijesh Kumar
Fong, Iat-Hang
Yeh, Chi-Tai
Lin, Chien-Min
Liu, Heng-Wei
author_sort Su, I-Chang
collection PubMed
description Glioblastoma multiforme (GBM) is a highly heterogeneous disease with a mesenchymal subtype tending to exhibit more aggressive and multitherapy-resistant features. Glioblastoma stem-cells derived from mesenchymal cells are reliant on iron supply, accumulated with high reactive oxygen species (ROS), and susceptible to ferroptosis. Temozolomide (TMZ) treatment is the mainstay drug for GBM despite the rapid development of resistance in mesenchymal GBM. The main interconnection between mesenchymal features, TMZ resistance, and ferroptosis are poorly understood. Herein, we demonstrated that a subunit of NADPH oxidase, CYBB, orchestrated mesenchymal shift and promoted TMZ resistance by modulating the anti-ferroptosis circuitry Nrf2/SOD2 axis. Public transcriptomic data re-analysis found that CYBB and SOD2 were highly upregulated in the mesenchymal subtype of GBM. Accordingly, our GBM cohort confirmed a high expression of CYBB in the GBM tumor and was associated with mesenchymal features and poor clinical outcome. An in vitro study demonstrated that TMZ-resistant GBM cells displayed mesenchymal and stemness features while remaining resilient to erastin-mediated ferroptosis by activating the CYBB/Nrf2/SOD2 axis. The CYBB maintained a high ROS state to sustain the mesenchymal phenotype, TMZ resistance, and reduced erastin sensitivity. Mechanistically, CYBB interacted with Nrf2 and consequently regulated SOD2 transcription. Compensatory antioxidant SOD2 essentially protected against the deleterious effect of high ROS while attenuating ferroptosis in TMZ-resistant cells. An animal study highlighted the protective role of SOD2 to mitigate erastin-triggered ferroptosis and tolerate oxidative stress burden in mice harboring TMZ-resistant GBM cell xenografts. Therefore, CYBB captured ferroptosis resilience in mesenchymal GBM. The downstream compensatory activity of CYBB via the Nrf2/SOD2 axis is exploitable through erastin-induced ferroptosis to overcome TMZ resistance.
format Online
Article
Text
id pubmed-10178261
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101782612023-05-13 NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation Su, I-Chang Su, Yu-Kai Setiawan, Syahru Agung Yadav, Vijesh Kumar Fong, Iat-Hang Yeh, Chi-Tai Lin, Chien-Min Liu, Heng-Wei Int J Mol Sci Article Glioblastoma multiforme (GBM) is a highly heterogeneous disease with a mesenchymal subtype tending to exhibit more aggressive and multitherapy-resistant features. Glioblastoma stem-cells derived from mesenchymal cells are reliant on iron supply, accumulated with high reactive oxygen species (ROS), and susceptible to ferroptosis. Temozolomide (TMZ) treatment is the mainstay drug for GBM despite the rapid development of resistance in mesenchymal GBM. The main interconnection between mesenchymal features, TMZ resistance, and ferroptosis are poorly understood. Herein, we demonstrated that a subunit of NADPH oxidase, CYBB, orchestrated mesenchymal shift and promoted TMZ resistance by modulating the anti-ferroptosis circuitry Nrf2/SOD2 axis. Public transcriptomic data re-analysis found that CYBB and SOD2 were highly upregulated in the mesenchymal subtype of GBM. Accordingly, our GBM cohort confirmed a high expression of CYBB in the GBM tumor and was associated with mesenchymal features and poor clinical outcome. An in vitro study demonstrated that TMZ-resistant GBM cells displayed mesenchymal and stemness features while remaining resilient to erastin-mediated ferroptosis by activating the CYBB/Nrf2/SOD2 axis. The CYBB maintained a high ROS state to sustain the mesenchymal phenotype, TMZ resistance, and reduced erastin sensitivity. Mechanistically, CYBB interacted with Nrf2 and consequently regulated SOD2 transcription. Compensatory antioxidant SOD2 essentially protected against the deleterious effect of high ROS while attenuating ferroptosis in TMZ-resistant cells. An animal study highlighted the protective role of SOD2 to mitigate erastin-triggered ferroptosis and tolerate oxidative stress burden in mice harboring TMZ-resistant GBM cell xenografts. Therefore, CYBB captured ferroptosis resilience in mesenchymal GBM. The downstream compensatory activity of CYBB via the Nrf2/SOD2 axis is exploitable through erastin-induced ferroptosis to overcome TMZ resistance. MDPI 2023-04-22 /pmc/articles/PMC10178261/ /pubmed/37175412 http://dx.doi.org/10.3390/ijms24097706 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Su, I-Chang
Su, Yu-Kai
Setiawan, Syahru Agung
Yadav, Vijesh Kumar
Fong, Iat-Hang
Yeh, Chi-Tai
Lin, Chien-Min
Liu, Heng-Wei
NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation
title NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation
title_full NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation
title_fullStr NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation
title_full_unstemmed NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation
title_short NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation
title_sort nadph oxidase subunit cybb confers chemotherapy and ferroptosis resistance in mesenchymal glioblastoma via nrf2/sod2 modulation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178261/
https://www.ncbi.nlm.nih.gov/pubmed/37175412
http://dx.doi.org/10.3390/ijms24097706
work_keys_str_mv AT suichang nadphoxidasesubunitcybbconferschemotherapyandferroptosisresistanceinmesenchymalglioblastomavianrf2sod2modulation
AT suyukai nadphoxidasesubunitcybbconferschemotherapyandferroptosisresistanceinmesenchymalglioblastomavianrf2sod2modulation
AT setiawansyahruagung nadphoxidasesubunitcybbconferschemotherapyandferroptosisresistanceinmesenchymalglioblastomavianrf2sod2modulation
AT yadavvijeshkumar nadphoxidasesubunitcybbconferschemotherapyandferroptosisresistanceinmesenchymalglioblastomavianrf2sod2modulation
AT fongiathang nadphoxidasesubunitcybbconferschemotherapyandferroptosisresistanceinmesenchymalglioblastomavianrf2sod2modulation
AT yehchitai nadphoxidasesubunitcybbconferschemotherapyandferroptosisresistanceinmesenchymalglioblastomavianrf2sod2modulation
AT linchienmin nadphoxidasesubunitcybbconferschemotherapyandferroptosisresistanceinmesenchymalglioblastomavianrf2sod2modulation
AT liuhengwei nadphoxidasesubunitcybbconferschemotherapyandferroptosisresistanceinmesenchymalglioblastomavianrf2sod2modulation